Hospices Civils De Lyon

Oncology and rare cancers

Clinical research covers advanced and metastatic solid tumours, with particular attention to mesothelioma, gastric adenocarcinoma, ovarian cancer, neuroendocrine carcinoma, thymic malignancies, anaplastic thyroid carcinoma, and gestational trophoblastic neoplasia. The portfolio also includes studies in metastatic prostate cancer and other treatment-resistant cancers.

  • Malignant pleural and peritoneal mesothelioma
  • Advanced gastric cancer
  • Rare thoracic and endocrine tumours
  • Gastro-enteropancreatic neuroendocrine neoplasms

Research interest extends to immunotherapy, targeted cancer treatment, and surgical or locoregional management in advanced disease.

Neurology, neuroimaging, and movement disorders

Trials address Parkinson disease, Tourette disorder, epilepsy, cluster headache, stroke, intracerebral haemorrhage, transient ischemic attack, and broader nervous system diseases. Several studies focus on brain receptor pathways, functional connectivity, and inflammatory imaging markers.

  • Parkinson disease
  • Epilepsy and seizure disorders
  • Tourette disorder
  • Stroke and cerebrovascular disease

There is also interest in PET-MRI, serotonergic pathways, and adrenergic receptor biology.

Pulmonary, critical care, and infectious disease

The sponsor funds studies in asthma, idiopathic pulmonary fibrosis, ventilator-acquired pneumonia, and septic shock. Research also includes inflammatory and immune-related respiratory conditions such as extra-pulmonary sarcoidosis.

  • Asthma
  • Idiopathic pulmonary fibrosis
  • Ventilator-acquired pneumonia
  • Septic shock

Additional work explores immune modulation in acute infection and respiratory failure.

Autoimmune, transplant, and haematology

Clinical activity includes systemic lupus erythematosus, ANCA-associated vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, renal transplantation, and allogeneic haematopoietic stem cell transplantation. These studies reflect interest in immune-mediated disease, graft outcomes, and transplant-related immunosuppression.

  • Systemic lupus erythematosus
  • ANCA-associated vasculitis
  • Kidney transplantation
  • Haematopoietic stem cell transplantation

Research also touches on graft rejection and immune recovery after transplantation.

Dermatology, ophthalmology, and paediatric care

Further trials involve Stevens-Johnson syndrome, toxic epidermal necrolysis, bilateral limbal stem cell deficiency, diabetic macular oedema, and cerebral palsy with pathological drooling. The portfolio also includes obesity in children and adolescents, postoperative pain, and drug dependence.

  • Severe bullous skin reactions
  • Limbal stem cell deficiency
  • Diabetic macular oedema
  • Paediatric neurological and functional disorders

These studies span skin regeneration, vision-threatening disease, and supportive care in paediatrics.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • [18F]CPFPX PET in Patients With Drug-Resistant Epilepsy and Healthy Subjects

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • A study using [11C]ORM-13070 to examine the effects of aging and Parkinson’s disease on specific brain receptors.

    Not yet recruiting

    2 1 1
    France
  • Study of dexmedetomidine and a drug combination for treating patients on mechanical ventilation with septic shock.

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Study evaluating the effect of levetiracetam on recovery in patients with intracerebral haemorrhage

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France
  • A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    France
  • Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

    Not yet recruiting

    2 1 1 1
    France